Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
BofA Securities Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Raises Target Price to $34
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
BofA Adjusts Price Target on Catalyst Pharmaceuticals to $34 From $33
Catalyst Pharmaceuticals Inc. Stock Falls 4.5%, Underperforms Competitors
Santhera Pharmaceuticals Secures Funding for Duchenne Muscular Dystrophy Drug in UK
